Comprehensive medication guide to Voydeya including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Commercially insured patients can reduce out-of-pocket costs to as low as $0 through the Alexion OneSource Copay Program (max $15,000 savings per year). Prior authorization is required by all major payers; specialty/non-preferred tier placement is standard. Medicare Part D covers Voydeya but manufacturer copay cards cannot be used by government beneficiaries.
Estimated Cash Pricing
Voydeya has no generic and is only available as a brand-name specialty drug. Retail pricing is approximately $4,043–$5,388 per 180-tablet supply; annual cost ranges from $50,000–$100,000 for danicopan alone. Discount cards (GoodRx, SingleCare) do not apply since it is dispensed exclusively through specialty pharmacy.
Medfinder Findability Score
35/100
Summarize with AI
On this page
Voydeya (danicopan) is a prescription oral medication and the first FDA-approved complement Factor D inhibitor. It was approved by the FDA on March 29, 2024, and is manufactured by Alexion Pharmaceuticals, Inc. (AstraZeneca). Voydeya is a first-in-class therapy, meaning no other drug in its specific category had been approved for any indication before it.
Voydeya is indicated as add-on therapy to ravulizumab (Ultomiris) or eculizumab (Soliris) for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, chronic, and potentially life-threatening blood disorder caused by a mutation in the PIGA gene that results in red blood cells lacking complement-regulatory surface proteins.
Voydeya comes as 50 mg and 100 mg film-coated oral tablets. The starting dose is 150 mg three times daily (one 50 mg + one 100 mg tablet together, three times per day). It can be taken with or without food. A dose escalation to 200 mg three times daily is possible after 4 weeks if hemoglobin response is insufficient. Voydeya is not approved as monotherapy and must be used in combination with a C5 inhibitor.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Voydeya works by selectively inhibiting complement Factor D, a serine protease enzyme that is a rate-limiting step in the alternative complement pathway. Factor D catalyzes the cleavage of Factor B, which is required to form C3 convertase — the enzyme that cleaves C3 into C3b. C3b then coats (opsonizes) red blood cells, marking them for destruction outside blood vessels (extravascular hemolysis, or EVH) in the spleen and liver.
By blocking Factor D, danicopan prevents the formation of C3 convertase, stops C3b opsonization, and breaks the amplification loop that drives EVH in PNH patients. This targets the upstream alternative pathway, complementing C5 inhibitors (eculizumab/ravulizumab) which block downstream intravascular hemolysis (IVH). Together, the combination provides comprehensive coverage against both IVH and EVH — the two main types of red blood cell destruction in PNH.
Approximately 10–20% of PNH patients on C5 inhibitors continue to experience clinically significant EVH, resulting in persistent anemia, fatigue, and transfusion dependence. The ALPHA Phase 3 trial (ALXN2040-PNH-301) demonstrated that adding Voydeya to an established C5 inhibitor regimen significantly improved hemoglobin levels at 12 weeks compared to placebo, with many patients achieving hemoglobin normalization and transfusion avoidance.
50 mg — film-coated tablet
White to off-white, round, film-coated. Printed with 'DCN' above '50'. Used as part of the 150 mg TID starting dose.
100 mg — film-coated tablet
White to off-white, round, film-coated. Printed with 'DCN' above '100'. Used in both 150 mg and 200 mg TID dosing.
150 mg TID — combination (50 mg + 100 mg tablets)
Starting dose: one 50 mg tablet + one 100 mg tablet taken together, three times daily, with or without food.
200 mg TID — two 100 mg tablets
Escalated dose: two 100 mg tablets taken together, three times daily. Used if hemoglobin does not increase by >2 g/dL after 4 weeks at 150 mg TID.
Voydeya is not on the FDA's drug shortage list, but it is one of the most access-restricted oral medications in the United States. The primary access barriers are structural: the VOYDEYA REMS program mandates prescriber certification, patient vaccination at least 2 weeks before the first dose, and dispensing exclusively through REMS-certified specialty pharmacies — primarily Onco360. Voydeya cannot be filled at any retail pharmacy (CVS, Walgreens, Rite Aid, etc.).
In addition to REMS requirements, prior authorization is required by virtually all insurance plans given Voydeya's annual cost of $50,000–$100,000. Typical timelines from prescription to first dose are 2–6 weeks when all requirements are in order. Insurance denials are common on first submission and often require appeals or peer-to-peer reviews.
If you are struggling to access Voydeya, medfinder can help you verify specialty pharmacy availability and navigate the access landscape for your prescription.
Voydeya is not a controlled substance, but due to the VOYDEYA REMS program, only physicians enrolled and certified in the REMS program can legally prescribe it. This effectively restricts prescribing to specialists who have completed the specific REMS certification process with Alexion.
Hematologists — primary prescribers; specialist in blood disorders including PNH
Hematologist-Oncologists — physicians managing both blood cancers and non-malignant blood diseases, enrolled in REMS
Primary care physicians, internists, nurse practitioners, and physician assistants cannot prescribe Voydeya. Telehealth options for initial prescribing are very limited — the REMS enrollment process, required vaccinations, and initial PNH assessment almost always require in-person visits with a REMS-certified hematologist. Established patients may be able to conduct some follow-up appointments via telehealth, but initial therapy requires in-person evaluation.
No. Voydeya (danicopan) is not a controlled substance and is not scheduled by the DEA. There is no DEA schedule associated with danicopan, and it does not have abuse or dependence potential that would warrant scheduling.
However, Voydeya does require a valid prescription from a REMS-certified hematologist. Because of the VOYDEYA REMS program's safety requirements — including mandatory vaccinations, prescriber certification, and specialty-pharmacy-only dispensing — access to Voydeya is more restricted than most non-controlled prescription drugs. Prescriptions cannot be called in to retail pharmacies and cannot be transferred between pharmacies.
Voydeya carries an FDA boxed warning for serious, life-threatening infections caused by encapsulated bacteria (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type B). The most common adverse reaction reported in ≥10% of patients is headache. Common side effects (≥5%) include:
Headache (≥10%)
Vomiting (≥5%)
Fever (pyrexia) (≥5%)
Elevated liver enzymes (ALT increase) (≥5%)
Hypertension (≥5%)
Pain in extremities (≥5%)
Increased triglycerides (<5%)
Serious infections (boxed warning): Life-threatening meningitis, pneumonia, or Hib disease from encapsulated bacteria — seek emergency care immediately if fever, severe headache, stiff neck, or rash develops
Pancreatitis (reported in clinical trials)
Cholecystitis (gallbladder inflammation)
Hepatotoxicity (liver damage from enzyme elevations) — monitor LFTs before and during treatment
Know what you need? Skip the search.
Empaveli (pegcetacoplan)
Subcutaneous C3 inhibitor given twice weekly at home via infusion pump. Monotherapy option for PNH, replacing C5 inhibitors. Addresses both intravascular and extravascular hemolysis.
Fabhalta (iptacopan)
Oral complement Factor B inhibitor (200 mg twice daily), approved as monotherapy for PNH. Can replace C5 inhibitors. Also approved for IgAN and C3G.
Ultomiris (ravulizumab)
IV infusion C5 inhibitor given every 8 weeks. Standard first-line therapy for PNH. Voydeya is designed as add-on to ravulizumab for patients with ongoing EVH.
Soliris (eculizumab)
IV infusion C5 inhibitor given every 2 weeks. Original first-line PNH therapy; biosimilars now available (Epysqli, Bkemv). Voydeya can be added to eculizumab for EVH.
Prefer Voydeya? We can find it.
Rosuvastatin (Crestor)
majorDanicopan significantly increases rosuvastatin exposure (BCRP + OATP inhibition). Rosuvastatin dose must not exceed 10 mg once daily when co-administered with Voydeya.
BCRP substrates (methotrexate, irinotecan, nitrofurantoin)
moderateDanicopan is a BCRP inhibitor. Concomitant use increases plasma concentrations of BCRP substrates. Monitor for adverse reactions; consider dose reduction.
P-gp substrates (apixaban, dabigatran, digoxin, colchicine, cyclosporine)
moderateDanicopan inhibits P-glycoprotein. May increase plasma concentrations of P-gp substrates. Dose adjustment may be necessary, especially where small concentration changes lead to serious adverse reactions.
Voydeya (danicopan) represents a significant advance for PNH patients who continue to suffer from extravascular hemolysis despite established C5 inhibitor therapy. As the first-in-class oral Factor D inhibitor, it fills a specific unmet need for the 10–20% of PNH patients who experience ongoing anemia, fatigue, and transfusion dependence on eculizumab or ravulizumab alone.
The main challenges with Voydeya are cost and access: it is only available through specialty pharmacy (primarily Onco360), requires REMS enrollment, mandatory vaccinations, and prior authorization from insurance. However, for eligible commercially insured patients, the Alexion OneSource Copay Program can reduce out-of-pocket costs to as low as $0 (maximum $15,000 annual savings). Contact Alexion OneSource at 1-888-765-4747 or visit alexiononesource.com for enrollment.
If you are having trouble finding or accessing Voydeya, medfinder is here to help. Submit your medication details and we'll contact specialty pharmacies on your behalf to find where your prescription can be filled.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini